Introduction
Fibroblast growth factors (FGF) are involved in many biological processes including embryonic development and cellular homeostasis in the adult [10, 11] . The 23 FGFs and the four known plasma membrane-associated receptors, the fibroblast growth receptors (FGFRs) transduce a variety of biochemical changes in developing and adult tissues [8, 13, 31] . The recently identified fibroblast growth factor, FGF-23, inhibits renal phosphate reabsorption and 1α,25-dihydroxyvitamin D (1α,25(OH)2D) synthesis [1, 7, 15, 21, 27, 34, 35, 38] . FGF-23 plays a role in the pathogenesis of a variety of hypophosphatemic disorders including autosomal dominant hypophosphatemic rickets, tumorinduced osteomalacia, and X-linked hypophosphatemic rickets [6, 22, 23] . Recently, the autosomal recessive disorder, familial tumoral calcinosis, characterized by ectopic calcifications and elevated serum phosphate levels, has been associated with a homozygous mis-sense mutation in the FGF-23 gene [4] . FGF-23 is expressed at high levels in the brain and bone [29, 30] and in low levels in a variety of tissues [1, 37] . The protein is synthesized as a 251-amino acid precursor protein with a 24-residue signal peptide. The role of the protein in phosphate homeostasis has been explored after the administration of the peptide to transporting epithelial cells [7] and mice, [22, 24, 26] by the transgenic overexpression of the protein, [2, 17, 28] and gene ablation experiments [20, 25, 29] . These experiments and several other recent in vivo studies demonstrate that FGF-23 is a phosphaturic factor that also counter-regulates 25-hydroxyvitamin D 1α-hydroxylase expression.
In autosomal dominant hypophosphatemic rickets (ADHR), a disease associated with low serum phosphorus and 1α,25(OH) 2 D concentrations and rickets, mutations in the FGF-23 gene result in the expression of a protein that is resistant to proteolysis and with an increased half-life [3, 6, 27, 34, 35] . Mutations in the gene alter the furin proconvertase recognition site (176RHTR179) in the protein such that the arginine residue at 176 is replaced by glutamine (R176Q) or the arginine residue at amino acid 179 is replaced by a glutamine (R179Q) or tryptophan residue (R179W). In contrast, individuals with tumoral calcinosis have elevated serum phosphate levels and elevated serum levels of the FGF-23 carboxyl terminal fragments [4, 32] . Shimada et al. [27] have tested the bioactivity of a biosynthetic carboxyl terminal fragment of FGF-23 (aa 180-251) and an N-terminal fragment of FGF-23 and have shown that in contrast to the phosphaturic action of the full-length protein, these peptide fragments are biologically inactive 24 h after their administration intraperitoneally to mice at a dose of 5 μg per mouse every 12 h. These results suggest that the processing of FGF-23 between R179 and S180 may abolish the phosphaturic activity of FGF-23. Alternatively, differential processing of the fragments and/or changes in serum half-life could obscure potential biological actions.
To more completely assess the biological activity of carboxyl terminal FGF-23 peptides, we performed solid phase peptide synthesis of FGF-23 carboxyl terminal fragments and compared their acute phosphaturic activity to that of full-length FGF-23. We now demonstrate that FGF-23 176-251, 180-251, 184-251, and 180-205 retain significant phosphaturic activity in rats. The shortest fragment of FGF-23, FGF-23 180-205, can effectively lower serum Pi concentrations in Fgf-23 −/− mice. These results suggest that residues 176 to residue 206 are important for transducing the phosphaturic activity. As these peptides are easily synthesized, they can be used to assess FGF-23 function instead of the native full-length protein that is difficult to synthesize in large amounts and is readily degraded. Furthermore, they can potentially be used for the treatment of disorders associated with hyperphosphatemia.
Materials and methods
Protein and peptide synthesis Synthesis of full-length recombinant 25-251 human FGF-23 (lacking the first 24 signal sequence amino acids) was carried out using bacterial protein expression methods. Human FGF-23 25-251 was expressed in pET28a(+), Escherichia coli Rosetta 2(DE3) cells (Novagen/EMD, San Diego, CA), at 20°C in the presence of the inducer, isopropyl β-D-thiogalactoside (0.1 mM). Cells were lysed at 4°C in lysis buffer (20 mM Na 2 HPO4, 1.0 M NaCl, 10 mM beta-mercaptoethanol, pH 7.0) with 4 mM phenylmethanesulfonyl fluoride using an ice-jacketed Bead Beater (Biospec Industries, Bartlesville, OK; eight cycles of 20 s on/2 min off). The cell lysate was centrifuged at 4°C at 20,000×g for 30 min. The supernatant was stirred at 4°C with 15 ml nickel chelating sepharose (Amersham/GE Healthcare Bio-Sciences, Piscataway, NJ) for 2 h. The resin was pelleted by centrifugation, extensively washed, and then finally washed in a column with 1 l lysis buffer at 4°C over 12 h. Protein was eluted with lysis buffer containing 1 M imidazole (80 ml) and dialyzed against lysis buffer before being loaded onto a 5-ml HisTrap column (Amersham/GE Healthcare). Protein was eluted by an imidazole gradient (0-1 M) in lysis buffer. Fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue/silver stain and by immunoblots (PhastTransfer; Amersham/GE Healthcare) using an affinity purified polyclonal antibody against hFGF-23 and goat anti-rabbit horse-radish peroxidase (HRP) secondary antibody (Dako, Carpinteria, CA), visualized by chemiluminescence (Roche, Indianapolis, IN). Fractions containing N-terminal 6× His 25-251 hFGF-23 were combined and dialyzed against 20 mM Na 2 HPO 4 , 5 mM beta-mercaptoethanol, pH 7.0, and loaded onto an HR5/5 Mono S column (Amersham/GE Healthcare) and eluted with a NaCl gradient (0-1 M). Mono S fractions were analyzed by SDS-PAGE/immunoblotting. Fractions containing highly purified 25-251 hFGF-23 (∼0.25 M NaCl) were pooled and further analyzed by N-terminal protein sequencing. FGF-23 25-251 was dialyzed against N 2 -purged 0.9% NaCl at 4°C before animal infusions.
The synthesis of five FGF-23 peptides (cf. Table 1 ) was performed in the Mayo Peptide Synthesis Facility by solid phase methods on an ABI 433A peptide synthesizer (Applied Biosystems, Foster City, CA) using protocols previously described for the synthesis of human amyloid-β peptides [18] . Briefly, FGF-23 peptides (0.1 mmol scale) were synthesized on NovaSyn TGA resin (Calbiochem-Novabiochem, San Diego, CA) using 1H-benzotriazole activation of N a -9-fluoroenylmethoxy-carbonyl (Fmoc) amino acid derivatives and synthesis protocols provided by the instrument's manufacturer. After completion of synthesis, all peptides were cleaved from the TGA resin support using 10 ml of a solution of 87.5% trifluoroacetic acid (TFA), 5% water, 5% phenol, and 2.5% triisopropylsilane (v/v/wt/v) for 2 h at 22°C. The cleaved peptides were then precipitated in 40 ml cold tertbutylmethyl ether and purified by reverse phase highperformance liquid chromatography on a C 18 Jupiter column (250 mm×21.2 mm, Phenomenex) using a binary gradient of 0.1% aqueous TFA containing 5% acetonitrile (buffer A) and 0.1% aqueous TFA containing 80% acetonitrile (buffer B). The calculated mass for each FGF-23 synthetic peptide was verified by electrospray ionization mass spectrometry using an MSQ single quadropole mass analyzer (Thermo Electron, San Jose, CA) using the following parameters: start m/z of 500, stop m/z of 2000, dwell time of 0.1 ms at 40 scans/min. Each spectrum was deconvoluted into a single mass using Bioworks Browser provided by Thermo Electron.
Animals All animal protocols were approved by the Institutional Animal Care and Use Committee of the Mayo Clinic or Harvard School of Dental Medicine. Male Sprague Dawley rats weighing 300 g were purchased from Harlan Sprague Dawley (Madison WI, USA). They were fed a rodent diet containing 0.7% phosphate. All animals were fasted overnight before the experiment. On the day of the experiment, rats were anesthetized with an intraperitoneal injection of 100-150 mg/kg body weight of 5-secbutyl-ethyl-2-thiobarbituricacid (Inactin, Byk Gulden Konstanz, Hamburg Germany). The rats were placed on a heated table to maintain body temperature between 36-38°C. After a tracheostomy, a PE 50 catheter was placed in the left carotid artery to monitor mean arterial blood pressure and to collect blood samples. Catheters were also placed in the left and right jugular veins for infusions. Inulin at 2% in 0.9% NaCl plus 4.5% bovine serum albumin (BSA) were infused at a rate of 1.2 ml/h in one catheter, and 0.9% NaCl was infused in the other catheter at a rate of 1.2 ml/h. A catheter (PE 90) was placed in the bladder for urine collection. Seven groups of animals were studied.
Acute infusion studies: group 1 For the vehicle time control, n=8. After a 90-min recovery period, one 30-min urine sample was taken (C1), and a blood sample was taken. One hour later, a second 60-min clearance was taken (C2). , n=6, group 7). The last peptide was tested to define the minimum length of a bioactive phosphaturic fragment of FGF-23. Opossum kidney cell Pi uptake This was performed as described by Bowe et al. [7] to test the effect of FGF-23 and FGF-23 180-251 on Na + -dependent phosphate transport in renal epithelia in culture. Briefly, Pi transport was studied in monolayers of opossum kidney (OK) cells. OK cell monolayers were rinsed twice with DMEM/F12 before the addition of medium containing peptide or vehicle. Plates were incubated in medium containing peptide or vehicle for 3 h before the uptake assay. Cells were gently washed twice with 0.5 ml of rinse solution (137 mM choline chloride, 5.4 mM KCl, 1.2 mM MgCl 2 , 2.8 mM CaCl 2 , 10 mM 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES; pH 7.4), and 10 mM Tris (pH 7.4)). Transport was initiated by the addition of 0.5 ml transport solution containing 137 mM NaCl, 5.4 mM KCl, 1.2 mM MgCl 2 , 2.8 mM CaCl 2 , 10 mM HEPES (pH 7.4), 10 mM Tris (pH 7.4), and 0.1 mM K 2 H 32 PO4 (0.5 mCi/ml). Cells were incubated for 10 min at 37°C, and transport was terminated by the addition of 0.5 ml ice-cold stop solution containing 137 mM NaCl, 14 mM Trizma base, and 10 mM sodium arsenate. After two additional washes with 0.5 ml cold stop solution, cells were solubilized by the addition of 0.5 ml of 0.5% sodium dodecyl sulfate for 30 min at room temperature. 32 P radioactivity was determined in the cell lysates. Pi transport was calculated as nanomoles of 32 P per milligram protein taken up over a 10-min period of time. Ratios between experimental and control cells were calculated, and results were expressed as a percentage of the uptake in control cells.
Chronic studies
Generation of stable OK cell lines expressing a V5-tagged Na + -Pi IIa transporter The cell line was generated as described earlier [5] to test the effect of FGF-23 and FGF-23 180-251 on the internalization of the Na + -Pi IIa transporter.
Immunohistochemistry of OK-Na + -P i -IIa-V5 cells The presence of the transporter on the cell surface was carried out using methods and reagents described earlier [5] .
Analytical methods Plasma and urine phosphate concentrations were determined using the method of Chen et al. [12] . Inulin concentrations in plasma and urine were determined using the anthrone method [14] . Sodium concentrations in urine were determined by ion selective electrode (EasyLyte Plus Analyzer, Medica, Bedford, MA 01730). Serum 1α,25(OH) 2 D concentrations were measured using an RIA kit (Diasorin, Stillwater, MN).
Statistical analysis Statistically significant differences between groups were evaluated by Student's t-test for comparison between two groups or by one-way analysis of variance followed by Tukey's test for multiple comparisons. All values were expressed as mean±SE. A p value less than 0.05 was considered to be statistically significant.
Results
All proteins and peptides were of the appropriate molecular mass (see Table 1 ). Data for groups 1-7, performed to determine the effect of the acute intravenous infusion of equimolar amounts of FGF-23 fragments in normal rats, are summarized in Table 2 . The glomerular filtration rate was stable throughout the experiment in all groups studied. In the vehicle-infused group, the fractional excretion of sodium (FE Na) and fractional excretion of phosphate (FE Pi) were stable throughout the experiment (Fig. 1) . As shown in Table 2 , full-length recombinant FGF-23 significantly increased the FE Pi (p<0.001) and FE Na (p=0.01). FGF-23 and FGF-23 fragments 176-251, 180-251, 184-251, 206-251, and 180-205 on the fractional increases in the excretions of phosphate (FE Pi) and sodium (FE Na) FGF-23 or FGF-23 180-251 directly inhibited radiolabeled phosphorus uptake in the standard in vitro assay using opossum proximal tubular epithelial cells (OK; Fig. 3 ). To assess the mechanism by which these agents altered phosphate transport, we examined the surface expression of an epitope-tagged sodium phosphate transporter, NaPi IIa-V5. Immunofluorescent data confirmed that the anti-V5 antibody readily detected plasma membrane-localized NaPi IIaV5, whereas there was no significant staining in the absence of the primary antibody (Fig. 4a,d ). Three-hour treatment of FGF-23 or FGF-23 180-251 resulted in significant decreases in the amount of NaPiIIa-V5 detected (Fig. 4b,c) . Similar decreases in immunodetection of NaPiIIa-V5 occurred after incubation with PTH 1-34 ( Fig. 4e) but not the inactive PTH 13-34 (Fig. 4f) .
Discussion
The present studies demonstrate that acute intravenous infusions of equimolar doses of full-length FGF-23 and FGF-23 176-251 result in similar increases in phosphate excretion. Infusion of FGF-23 fragments 180-251, 180-205, and 184-251 also significantly increase phosphate excretion, although the magnitude of the increase in phosphate excretion is less than the phosphaturic response observed with infusion of full-length FGF-23 or FGF-23 fragment 176-251. Of interest, these bioactive fragments also increase sodium excretion when administered over the short-term. This is very likely due to the movement of sodium ions along with phosphate in the proximal tubule. With long-term administration, the sodium wasting is no longer seen, perhaps due to increased sodium reabsorption in the distal tubule.
The effects of the acute infusion of full-length FGF-23 on phosphate excretion are consistent with the in vivo studies by Shimada et al. [24, 26, 27] and Schiavi and Kumar [22] in mice, which demonstrate that administration of recombinant full-length FGF-23 increases phosphate excretion. However, in contrast to subsequent studies by Shimada et al. [27] , in which neither the N-terminal or Cterminal fragments of FGF-23 affected serum phosphate or phosphate excretion, in the present study, we show that the infusion of the carboxyl fragments of FGF-23 176-251, 180-205, 184-251, and 180-251 all significantly increase phosphate excretion. Of the peptides tested, only FGF-23 206-251 did not exhibit any biologic activity. The precise reason for the differences in bioactivity of the fragments tested by us compared to those tested by Shimada et al. [27] is not known, although we used chemically synthesized peptides, whereas previous studies applied biosynthetic protein fragments.
To validate our in vivo observations that various Cterminal fragments are bioactive, we also injected the smallest C-terminal fragment (180-205) into Fgf-23 −/− knockout mice and found a significant decrease in serum phosphate levels when compared to vehicle-injected Fgf-23 −/− mice [19, 29] ; these results suggest that C-terminal fragments could alter phosphate homeostasis in Fgf-23 −/− knockout mice and that only a small part of the FGF-23 protein has the potential to be used for treatment of diseases with hyperphosphatemia.
The in vitro studies demonstrate that similar to Parathyroid hormone (PTH), FGF-23 and FGF-23 180-251 inhibit sodium-phosphate transport by reducing the amount of plasma membrane-localized NaPi IIa. FGF-23 contains a consensus binding domain for FGFRs, and several studies have suggested that FGF-23 may bind and activate signaling through one or more FGFRs [36, 39, 40] . Recent in vivo genetic manipulation studies suggest that both FGF-23 and KLOTHO act through a common signaling pathway [19] and that KLOTHO facilitates FGF-23 binding to an FGFR [16, 33] . Of relevance is the absence of the The role of FGF-23 in the pathogenesis of ADHR has been shown to be due to mutations in the FGF-23 gene that result in the production of a mutant protein in which the amino acid sequence of a furin proconvertase cleavage site (176RHTR179) is altered (R176Q, R179Q, and R179W), rendering the mutant FGF-23 resistant to proteolysis [1, 34, 35] . The mutant FGF-23 protein has a prolonged half-life [1, 3, 27, 34, 35] . Our studies suggest that although furin cleavage between residues 176 and 179 results in a reduction in bioactivity of FGF-23, significant bioactivity persists with fragments that extend from carboxyl terminal amino acid residue 180 up to residue 206. This, in turn, suggests that further cleavage of FGF-23 in the carboxyl terminal domain needs to occur to render the molecule inactive. Indeed, Campos et al. [9] have demonstrated the presence of PHEX cleavage sites at amino acid residue 183 and 215. Potential PHEX cleavage sites also exist at residues 186, 188, and 208, all of which may play a role in altering the bioactivity of the FGF-23. As the 180-205 fragment of FGF-23 is bioactive, it is likely that sites carboxyl-terminal of residue 205 are important in the proteolytic processing and bio-inactivation of FGF-23.
It is interesting to note that patients with tumoral calcinosis have elevated concentrations of FGF-23 measured by an assay that detects carboxyl-terminal fragments of FGF-23 [4, 32] . In contrast, these patients have normal or low-normal concentrations of intact FGF-23. Our data would suggest that the carboxyl-terminal fragments circulating in patients with tumoral calcinosis are different from those tested by us. Alternatively, if FGF-23 fragments found in the circulation of patients with tumoral calcinosis are similar to those tested in our studies, their concentrations might be considerably lower than those achieved in our experiments.
In conclusion, we have identified the phosphaturic, bioactive domain of FGF-23 and show that it is present in the 180-205 region of the protein.
